2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update

Huang, Zoufang; Chavda, Vivek P.; Vora, Lalitkumar K.; Gajjar, Normi D.; Apostolopoulos, Vasso; Shah, Nirav; Chen, Zhe‐Sheng

doi:10.3389/fphar.2022.899633

Cited by 24 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are few standard drugs available in the market that are recently approved by FDA in the USA; however, repurposing drugs is a beneficial solution, that provides a better, immediate strategy to tackle the disease. Presently available treatments include drugs of small size molecules that prevent the entry of the virus into host cells or prevent the assembly and block replication of viruses [ 13 , 49 – 53 ]. The literature showed that remdesivir reduces the recovery time of hospitalized patients, thus reducing mortality [ 54 ].…”

Section: Current Scenario: Transition In Covid-19 Managementmentioning

confidence: 99%

Recent review of COVID-19 management: diagnosis, treatment and vaccination

et al. 2022

Self Cite

View full text Add to dashboard Cite

The idiopathic Coronavirus disease 2019 (COVID-19) pandemic outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global proportions; the World Health Organization (WHO) declared it as a public health emergency during the month of January 30, 2020. The major causes of the rise of new variants of SARS-CoV-2 are genetic mutations and recombination. Some of the variants with high infection and transmission rates are termed as variants of concern (VOCs) like currently Omicron variants. Pregnant women, aged people, and immunosuppressed and compromised patients constitute the most susceptible human population to the SARS-CoV-2 infection, especially to the new evolving VOCs. To effectively manage the pathological condition of infection, the focus should be directed towards prevention and prophylactic approach. In this narrative review, we aimed to analyze the current scenario of COVID-19 management and discuss the treatment and prevention strategies. We also focused on the complications prevalent during the COVID-19 and post-COVID period and to discuss the novel approaches developed for mitigation of the global pandemic. We have also emphasized on the COVID-19 management approaches for the special population including children, pregnant women, aged groups, and immunocompromised patients. We conclude that the advancements in therapeutic and pharmacological domains have provided opportunities to develop and design novel diagnosis, treatment, and prevention strategies. New advanced techniques such as RT-LAMP, RT-qPCR, High-Resolution Computed Tomography, etc., efficiently diagnose patients with SARS-CoV-2 infection. In the case of treatment options, new drugs like paxlovid, combinations of β-lactum drugs and molnupiravir are found to be effective against even the new emerging variants. In addition, vaccination is an essential approach to prevent the infection or to reduce its severity. Vaccines for against COVID-19 from Comirnaty by Pfizer-BioNTech, SpikeVax by Moderna, and Vaxzevria by Oxford-AstraZeneca are approved and used widely. Similarly, numerous vaccines have been developed with different percentages of effectiveness against VOCs. New developments like nanotechnology and AI can be beneficial in providing an efficient and reliable solution for the suppression of SARS-CoV-2. Public health concerns can be efficiently treated by a unified scientific approach, public engagement, and better diagnosis.

show abstract

Section: Current Scenario: Transition In Covid-19 Managementmentioning

confidence: 99%

Recent review of COVID-19 management: diagnosis, treatment and vaccination

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The table below shows IC 50 values obtained for αvβ 6 integrin inhibition for a series of exemplary compounds. …”

Section: Important Compound Classesmentioning

confidence: 99%

SARS-CoV-2: Novel Therapeutic Approaches for Diagnosis and Treatment

Kargbo

2022

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

“…The pandemic caused by the coronavirus disease (COVID-19) has had a substantial impact on human populations, resulting in significant morbidity and mortality [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ]. Globally, there are 636 million reported cases of COVID-19 (as per WHO) [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

et al. 2023

View full text Add to dashboard Cite

The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of the prodrug molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the RNA-dependent RNA polymerase (RdRp) enzyme, which is responsible for replicating the viral genome during the replication process of certain types of viruses. It works by disrupting the normal function of the RdRp enzyme, causing it to make mistakes during the replication of the viral genome. These mistakes can prevent the viral RNA from being transcribed, converted into a complementary DNA template, translated, or converted into a functional protein. By disrupting these crucial steps in the viral replication process, molnupiravir can effectively inhibit the replication of the virus and reduce its ability to cause disease. This review article sheds light on the impact of molnupiravir and its metabolite on SARS-CoV-2 variants of concern, such as delta, omicron, and hybrid/recombinant variants. The detailed mechanism and molecular interactions using molecular docking and dynamics have also been covered. The safety and tolerability of molnupiravir in patients with comorbidities have also been emphasized.

show abstract

2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update

Cited by 24 publications

References 49 publications

Recent review of COVID-19 management: diagnosis, treatment and vaccination

Recent review of COVID-19 management: diagnosis, treatment and vaccination

SARS-CoV-2: Novel Therapeutic Approaches for Diagnosis and Treatment

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Contact Info

Product

Resources

About